Earnings ·
Virax Biolabs Group Limited reported audited financial results for fiscal year 2026, showing $6.4 million in cash and…
VRAXVirax Biolabs Group Ltd
Virax Biolabs Group Limited reported audited financial results for fiscal year 2026, showing $6.4 million in cash and $8.3 million in total assets as of March 31, 2026. The company completed the exercise of preferred investment options on July 10, 2026, generating approximately $3.3 million in gross proceeds. Following a 1-for-25 share consolidation, Nasdaq confirmed on July 13, 2026, that the company regained compliance with minimum bid price requirements. Additionally, the company entered a multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets. Biotechnology company focused on immune response detection and in vitro diagnostic technologies.